Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03029858

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:18.897650+00:00

Published At

2017-01-24T00:00:00+00:00

Record Updated At

2017-01-24

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Small Cell Lung Cancer, Polygonal Type"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-01-24"

protocolSection.identificationModule.nctId

"NCT03029858"

protocolSection.identificationModule.officialTitle

"Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

[]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Small Cell Lung Cancer, Polygonal Type (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.